Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipatasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT3 known ✓ | Q9Y243 | 20/20 | 1.00 |
| ▸ | AKT1 known ✓ | P31749 | 19/20 | 1.00 |
| ▸ | AKT2 known ✓ | P31751 | 19/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 1/20 | 1.00 |
| ▸ | PRKG1 | Q13976 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipatasertib SCHEMBL31658211 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL29881570 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL29356998 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL17424852 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191491 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191495 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191492 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL191496 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL19867534 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 | |
| Ipatasertib SCHEMBL27128127 | 1.00 | AKT3 (1.00) | AKT3AKT1AKT2PIK3CAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 478 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440492-B2 | Pharmaceutical compositions comprising AKT protein kinase inhibitors | GENENTECH, INC. (US) | 2025-10-14 | — | — | US | claimed |
| US-20250281489-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH INC (US) | 2025-09-11 | — | — | US | claimed |
| EP-4613333-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-10 | — | — | EP | claimed |
| EP-3496722-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2025-07-16 | — | — | EP | claimed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | claimed |
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2025-05-15 | — | — | US | claimed |
| CN-115350192-B | Pharmaceutical compositions comprising inhibitors of Akt protein kinase | 豪夫迈·罗氏有限公司 | 2025-05-13 | — | — | CN | claimed |
| US-20250009749-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORS | GENENTECH INC (US) | 2025-01-09 | — | — | US | claimed |
| US-11969426-B2 | Pharmaceutical compositions comprising Akt protein kinase inhibitors | GENENTECH, INC. (US) | 2024-04-30 | — | — | US | claimed |
| EP-3617330-B1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH INC (US) | 2023-12-27 | — | — | EP | claimed |
| EP-2402325-B1 | Hydroxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2015-08-26 | — | — | EP | claimed |
| EP-2858989-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL - CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | Genentech, Inc. (US) | 2015-04-15 | — | — | EP | claimed |
| US-8853199-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-10-07 | — | — | US | claimed |
| US-20140031259-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | GENENTECH, INC. (US) | 2014-01-30 | — | — | US | claimed |
| WO-2013173811-A1 | AMORPHOUS FORM OF AN AKT INHIBITING PYRIMIDINYL - CYCLOPENTANE COMPOUND, COMPOSITIONS AND METHODS THEREOF | GENENTECH, INC. (US) | 2013-11-21 | — | — | WO | claimed |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | GENENTECH, INC. (US) | 2013-03-07 | — | — | US | claimed |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2012-09-13 | — | — | US | claimed |
| EP-2402325-A2 | Hydroxylated and methoxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors | Array Biopharma, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | claimed |
| EP-2049501-B1 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-09-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969426-B2 | Pharmaceutical compositions comprising Akt protein kinase inhibitors | PIK3CA, AKT1, AKT2 | AKT3 5/4885AKT1 2/4885AKT2 3/4885 |
| US-20250281489-A1 | BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS | TP53, PIK3CA, MKI67 | AKT3 11/4885AKT1 21/4885AKT2 16/4885 |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | AKT3 3951/4885AKT1 3905/4885AKT2 3986/4885 |
| US-20250009749-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, AKT2 | AKT3 5/4885AKT1 2/4885AKT2 3/4885 |
| US-20130059859-A1 | PREDICTIVE BIOMARKERS FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY | PIK3R2, PIK3R1, AKT2 | AKT3 4/4885AKT1 5/4885AKT2 3/4885 |
| US-12440492-B2 | Pharmaceutical compositions comprising AKT protein kinase inhibitors | PIK3CA, AKT1, AKT2 | AKT3 5/4885AKT1 2/4885AKT2 3/4885 |
| US-20120232055-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT3 4/4885AKT1 1/4885AKT2 2/4885 |
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | AKT3 4/4885AKT1 1/4885AKT2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.